Volume 1 Issue 1 | Cancer Discovery | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Volume 1, Issue 1

1 June 2011

Cover Image

Cover Image

A structural model shows dasatinib bound to the discoidin domain receptor 2 (DDR2) kinase. Hammerman and colleagues identified DDR2 as a potential therapeutic target in a subset of lung squamous cell carcinomas (SCC). They also found that dasatinib inhibited DDR2, and they observed a clinical response in one patient. These findings warrant further clinical evaluation of this drug and target in a subset of SCC patients. For details, please see the article by Hammerman and colleagues on page 78.
Table of Contents

ISSN 2159-8274

EISSN 2159-8290